Welcome to our dedicated page for Axogen news (Ticker: AXGN), a resource for investors and traders seeking the latest updates and insights on Axogen stock.
Axogen, Inc. develops and commercializes surgical solutions for peripheral nerve regeneration and repair. The company’s recurring updates center on its portfolio for restoration of peripheral nerve function, including Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™.
Company news also includes quarterly and annual financial results, revenue guidance, gross margin and cash metrics, investor-conference participation, FDA-related developments for Avance, and capital-structure actions involving common stock. These updates connect operating performance with Axogen’s commercial activity in nerve repair products across its target markets.
Axogen, a leader in surgical solutions for peripheral nerve injuries, announced that CEO Karen Zaderej will present at the JP Morgan 41st Annual Healthcare Conference in San Francisco on January 12, 2023, at 9:45 a.m. PST. The presentation will be available via live webcast on Axogen's Investors page, with a replay accessible for 90 days. Axogen specializes in technologies for nerve regeneration and repair, offering products like Avance® Nerve Graft and Axoguard Nerve Connector®. These solutions aim to restore nerve function and improve patients' quality of life.
Axogen, Inc. (NASDAQ: AXGN) announced its collaboration with the Donate Life organization, showcasing the stories of two patients benefiting from donated nerve tissue. Bri Majsiak, who underwent a mastectomy and nerve reconstruction using Avance Nerve Graft, will ride on the 2023 Donate Life Rose Parade Float. The event occurs on January 2, 2023, in Pasadena. Madelyn Nicpon, also an Avance Nerve Graft recipient, is honored posthumously through a floragraph on the float. This marks Axogen's tenth year co-sponsoring the float, emphasizing the vital role of organ and tissue donation.
Axogen, Inc. (NASDAQ: AXGN) reported third-quarter 2022 financial results, showcasing a net revenue of $37.0 million, an 18% increase year-over-year. The gross margin improved slightly to 83.3%. Despite a net loss of $4.3 million ($0.10 per share), this marks an improvement from a $7.1 million loss in Q3 2021. Adjusted net loss was narrowed to $0.4 million, with an adjusted EBITDA of $0.4 million. Cash and equivalents totaled $59.4 million, indicating a decrease due to capital expenditures for a new facility. The company revised its 2022 revenue guidance to $137.5 million to $140.0 million.
Axogen, Inc. (NASDAQ: AXGN) announced participation in key investor conferences in November and December 2022. CEO Karen Zaderej will engage in a fireside chat at the Jefferies London Healthcare Conference on November 15 and present at the Piper Sandler Healthcare Conference on November 30. CFO Peter Mariani will take part in the Canaccord Genuity Forum on November 17. Both executives will join a panel at the Cantor Medical & Aesthetic Conference on December 8. Webcasts will be accessible live on Axogen's Investors page, with replays available for 90 days.
Axogen, Inc. (NASDAQ: AXGN) announced the appointment of Dr. Adrian Tyndall as an independent board member effective December 13, 2022. Dr. Tyndall, currently the Executive Vice President for Health Affairs and Dean of Morehouse School of Medicine, brings extensive experience in emergency medicine and trauma research. His expertise is expected to enhance Axogen's mission in peripheral nerve repair. Additionally, founding director Dr. Mark Gold will retire from the board on the same date. The board expressed gratitude for Dr. Gold's contributions during his tenure.
Axogen, Inc. (NASDAQ: AXGN), a leader in surgical solutions for peripheral nerve injuries, will report its third quarter 2022 financial results on November 8, 2022, before market opening. The company will host an investment-community conference call at 8:00 a.m. ET on the same day. Interested participants can join via phone or through the company's website. Axogen provides innovative products for nerve repair, including Avance® Nerve Graft and Axoguard products, aimed at restoring nerve function and improving patient quality of life.
Axogen, a leader in peripheral nerve repair, will participate in the 77th Annual Meeting of the American Society for Surgery of the Hand (ASSH) from September 29 to October 1, 2022, in Boston. The company will host a symposium on nerve reconstruction data on September 30, featuring insights from recent trials. Attendees can engage in hands-on demonstrations at Booth #815 and meet top scientists at the Innovation Lab. Additionally, Axogen supports various ASSH initiatives, including scholarships and skills bootcamps, reflecting its commitment to advancing nerve repair solutions.
Axogen reported Q2 2022 net revenue of $34.5 million, a 3% increase year-over-year, with a 9% increase when excluding Avive revenue. Gross margin improved to 81.8%, up from 78.9% in Q2 2021. The adjusted net loss narrowed to $2.6 million, or $0.06 per share. Cash and equivalents decreased to $64.3 million, primarily due to investments in a new processing facility. Axogen anticipates 2022 revenue between $135 million and $142 million, indicating 10% to 15% growth, with full-year gross margin expected above 80%.
Axogen, a leader in peripheral nerve injury solutions, announces that CEO Karen Zaderej will present at the Canaccord Genuity's 42nd Annual Growth Conference in Boston on August 10, 2022, at 12:30 p.m. ET. The presentation will be webcast live on the company's Investors page, with a replay available for 90 days.
Axogen focuses on developing technologies for nerve regeneration, offering products like Avance® Nerve Graft and Axoguard®, designed to restore nerve function and improve patient quality of life.
Axogen (AXGN) has announced organizational updates aimed at enhancing market development and innovation following strong preliminary second-quarter revenue of approximately $34.4 million, a 2% increase year-over-year. Changes include the sales team reporting directly to CEO Karen Zaderej and plans to appoint a new chief marketing officer. The company reaffirms its full-year revenue guidance of $135 million to $142 million with a gross margin above 80%. Further financial details will be released on August 3, 2022.